News

Alpine’s Dual Inhibitor ALPN-101 Reduces Immune Cell Activation in Preclinical Models of Sjögren’s Syndrome

Alpine Immune Sciences‘ ALPN-101, a treatment for inflammatory and autoimmune diseases that works by inhibiting two key pathways — ICOS and CD38 — is better at reducing immune cell activity than a combination of treatments targeting these molecules individually, suggests a study in cells and animal models of Sjögren’s…